This year, U.S. VC funding into the life sciences sector has cooled: Q1 softness was followed by a decade low in VC transactions in Q2. Despite the moderation in dealmaking volume, investors continued to deploy sizable...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2022 include:
• The industry generated $6.2 billion in deal value across 352 deals in Q3, exhibiting further quarterly...more